Results 91 to 100 of about 5,909,902 (374)

Rationale for tau aggregation inhibitor therapy in Alzheimer's disease and other tauopathies [PDF]

, 2010
Preprin
Harrington, Charles R, Storey, John M D, Wischik, Claude M, Wischik, Damon J   +3 more
core   +1 more source

Tau protein liquid–liquid phase separation can initiate tau aggregation

The EMBO Journal, 2018
The transition between soluble intrinsically disordered tau protein and aggregated tau in neurofibrillary tangles in Alzheimer's disease is unknown. Here, we propose that soluble tau species can undergo liquid–liquid phase separation (LLPS) under cellular conditions and that phase‐separated tau droplets can serve as an intermediate toward tau aggregate
Susanne Wegmann, Bahareh Eftekharzadeh, Katharina Tepper, Katarzyna M Zoltowska, Rachel E Bennett, Simon Dujardin, Pawel R Laskowski, Danny MacKenzie, Tarun Kamath, Caitlin Commins, Charles Vanderburg, Allyson D Roe, Zhanyun Fan, Amandine M Molliex, Amayra Hernandez‐Vega, Daniel Muller, Anthony A Hyman, Eckhard Mandelkow, J Paul Taylor, Bradley T Hyman   +19 more
openaire   +7 more sources

Tau Protein Dysfunction after Brain Ischemia [PDF]

Journal of Alzheimer's Disease, 2018
Brain ischemia comprises blood-brain barrier, glial, and neuronal cells. The blood–brain barrier controls permeability of different substances and the composition of the neuronal cells ‘milieu’, which is required for their physiological functioning. Recent evidence indicates that brain ischemia itself and ischemic blood-brain barrier dysfunction is ...
Pluta, Ryszard, Ułamek-Kozioł, Marzena, Januszewski, Sławomir, Czuczwar, Stanisław J.   +3 more
openaire   +2 more sources

Plasma Proteomic Signatures for Alzheimer's Disease: Comparable Accuracy to ATN Biomarkers and Cross‐Platform Validation

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background There is growing recognition of the potential of plasma proteomics for Alzheimer's Disease (AD) risk assessment and disease characterization. However, differences between proteomics platforms introduce uncertainties regarding cross‐platform applicability.
Manyue Hu, Oliver Robinson, Christina M. Lill, Anna Matton, Raquel Puerta, Pilar Sanz, Merce Boada, Agustín Ruiz, Lefkos Middleton, for the Alzheimer's Disease Neuroimaging Initiative   +9 more
wiley   +1 more source

α-Synuclein Aggregated with Tau and β-Amyloid in Human Platelets from Healthy Subjects: Correlation with Physical Exercise

Frontiers in Aging Neuroscience, 2018
The loss of protein homeostasis that has been associated with aging leads to altered levels and conformational instability of proteins, which tend to form toxic aggregates.
Simona Daniele, Deborah Pietrobono, Jonathan Fusi, Annalisa Lo Gerfo, Eugenio Cerri, Lucia Chico, Caterina Iofrida, Lucia Petrozzi, Filippo Baldacci, Chiara Giacomelli, Fabio Galetta, Gabriele Siciliano, Ubaldo Bonuccelli, Maria L. Trincavelli, Ferdinando Franzoni, Claudia Martini   +15 more
doaj   +1 more source

Targeting tauopathy with engineered tau-degrading intrabodies [PDF]

, 2019
BACKGROUND: The accumulation of pathological tau is the main component of neurofibrillary tangles and other tau aggregates in several neurodegenerative diseases, referred to as tauopathies.
Gallardo, Gilbert, Holtzman, David M, Jiang, Hong, Leyns, Cheryl E G, Lin, Kent H, Mann, Carolyn N, Ricardez, Sara M, Wong, Connie H   +7 more
core   +1 more source

O-GlcNAc modification blocks the aggregation and toxicity of the protein α-synuclein associated with Parkinson's disease. [PDF]

, 2015
Several aggregation-prone proteins associated with neurodegenerative diseases can be modified by O-linked N-acetyl-glucosamine (O-GlcNAc) in vivo. One of these proteins, α-synuclein, is a toxic aggregating protein associated with synucleinopathies ...
Ambroso, Mark R, Arnold, Don B, Langen, Ralf, Lewis, Yuka E, Lin, Yu Hsuan, Marotta, Nicholas P, Pratt, Matthew R, Roth, Maxwell T, Zaro, Balyn W   +8 more
core   +2 more sources

Mitochondrial dysfunction - the beginning of the end in Alzheimer's disease? Separate and synergistic modes of tau and amyloid-β toxicity

Alzheimer's Research & Therapy, 2011
The pathology of Alzheimer's disease (AD) is characterized by amyloid plaques (aggregates of amyloid-β (Aβ)) and neurofibrillary tangles (aggregates of tau) and is accompanied by mitochondrial dysfunction, but the mechanisms underlying this dysfunction ...
Anne Eckert, K. Schmitt, Jürgen Götz
semanticscholar   +1 more source

Tau Protein and Adult Hippocampal Neurogenesis [PDF]

Frontiers in Neuroscience, 2012
Tau protein is a microtubule-associated protein found in the axonal compartment that stabilizes neuronal microtubules under normal physiological conditions. Tau metabolism has attracted much attention because of its role in neurodegenerative disorders called tauopathies, mainly Alzheimer disease.
Almudena eFuster-Matanzo, Almudena eFuster-Matanzo, María eLlorens-Martín, María eLlorens-Martín, Jerónimo eJurado-Arjona, Jerónimo eJurado-Arjona, Jesus eAvila, Jesus eAvila, Félix eHernández, Félix eHernández   +9 more
openaire   +5 more sources

Chronological and Spatial Distribution of Skeletal Muscle Fat Replacement in FHL1‐Related Myopathies

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives Variants in the FHL1 gene cause FHL1‐related myopathies (FHL1‐RMs), a group of neuromuscular disorders with diverse clinical presentations. This study aimed to comprehensively characterize the spatial and temporal patterns of skeletal muscle fat replacement throughout the whole body in FHL1‐RMs, to examine disease progression over ...
Rui Shimazaki, Satoru Noguchi, Hotake Takizawa, Yasushi Oya, Yuji Takahashi, Hirofumi Komaki, Hajime Arahata, Shinichiro Hayashi, Ichizo Nishino   +8 more
wiley   +1 more source